Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
51 studies found for:    physical | urticaria
Show Display Options
Rank Status Study
1 Recruiting Pathogenesis of Physical Induced Urticarial Syndromes
Conditions: Autoinflammatory Syndromes;   Physical Urticaria
Intervention:
2 Completed Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria
Condition: Urticaria
Interventions: Drug: Bilastine;   Drug: Levocetirizine;   Drug: Placebo
3 Completed
Has Results
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
Condition: Chronic Urticaria
Interventions: Drug: Omalizumab 75-375 mg;   Drug: Placebo to omalizumab;   Drug: Loratadine;   Drug: Clemastine
4 Active, not recruiting Cold Urticaria Treatment With Xolair
Condition: Cold Contact Urticaria
Interventions: Drug: Omalizumab;   Drug: Placebo
5 Not yet recruiting Efficacy of Levocetirizine Fourfold Dosage in Chronic Spontaneous Urticaria
Condition: Chronic Spontaneous Urticaria
Interventions: Drug: Levocetirizine (as levocetirizine dihydrochloride), 5mg ( then 20 mg) per day . Oral administration.;   Drug: Levocetirizine, (as levocetirizine dihydrochloride) 20 mg ( then 5 mg) per day. Oral administration.
6 Completed
Has Results
Observation of Side Effects and Effectiveness of Desloratadine (Aerius) Syrup in Filipino Children (Study P05634)
Conditions: Rhinitis, Allergic, Seasonal;   Rhinitis, Allergic, Perennial;   Urticaria
Intervention: Drug: Desloratadine Syrup
7 Recruiting Chronic Urticaria - Long Term Assessment of Effects of Rupatadine
Condition: Chronic Urticaria
Interventions: Drug: 10 mg Rupatadine on demand;   Drug: 10 mg Rupatadine;   Drug: 20 mg Rupatadine;   Drug: 10 mg Rupatadine on demand (sham updosing to 20 mg)
8 Completed
Has Results
Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: IGE025;   Drug: placebo
9 Completed
Has Results
Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)
Condition: Idiopathic Solar Urticaria
Interventions: Drug: Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209);   Drug: Ti02 pigmentary 3% alone (formula RV3131A-MV1211);   Drug: bisoctrizole 10% alone (formula RV3131A-MV1237);   Drug: Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213);   Drug: Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329);   Drug: Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212);   Drug: Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)];   Drug: V0096 CR vehicle (formula RV3131A-MV1197)
10 Completed An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540)
Condition: Urticaria
Intervention: Drug: Desloratadine
11 Completed Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria
Condition: Urticaria
Interventions: Drug: Cetirizine;   Drug: Desloratadine;   Drug: Fexofenadine;   Drug: Ebastine;   Drug: Bilastine
12 Recruiting Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Conditions: Aggressive Systemic Mastocytosis;   Mast Cell Leukemia;   Systemic Mastocytosis
Interventions: Drug: brentuximab vedotin;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: questionnaire administration
13 Completed Urticaria Facticia Treatment With Omalizumab (UFO)
Condition: Symptomatic Dermographism
Interventions: Drug: Omalizumab;   Drug: Placebo
14 Terminated Efficacy of Rupatadine 5, 10 and 20 Mg in Chronic Idiopathic Urticaria
Condition: Urticaria
Intervention: Drug: RUPATADINE (ANTI-HISTAMINE)
15 Recruiting Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
Conditions: Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue;   Pyoderma Gangrenosum;   Erosive Pustular Dermatosis of the Scalp;   Sweet's Syndrome;   Behcet's Disease;   Bowel-associated Dermatosis-arthritis Syndrome;   Pustular Psoriasis;   Acute Generalized Exanthematous Pustulosis;   Keratoderma Blenorrhagicum;   Sneddon-Wilkinson Disease;   IgA Pemphigus;   Amicrobial Pustulosis of the Folds;   Infantile Acropustulosis;   Transient Neonatal Pustulosis;   Neutrophilic Eccrine Hidradenitis;   Rheumatoid Neutrophilic Dermatitis;   Neutrophilic Urticaria;   Still's Disease;   Erythema Marginatum;   Unclassified Periodic Fever Syndromes / Autoinflammatory Syndromes;   Dermatitis Herpetiformis;   Linear IgA Bullous Dermatosis;   Bullous Systemic Lupus Erythematosus;   Inflammatory Epidermolysis Bullosa Aquisita;   Neutrophilic Dermatosis of the Dorsal Hands (Pustular Vasculitis);   Small Vessel Vasculitis Including Urticarial Vasculitis;   Erythema Elevatum Diutinum;   Medium Vessel Vasculitis
Intervention: Procedure: Collection of biological samples
16 Active, not recruiting A Long-Term Examination of Asthma From Childhood Through Adolescence
Conditions: Asthma;   Dermatitis, Atopic;   Rhinitis;   Urticaria
Intervention:
17 Active, not recruiting The Validity, Reliability and Interpretability of Thai-version of Chronic Urticaria Quality of Life Questionnaire
Condition: Chronic Urticaria
Intervention: Other: CU-Q2oL
18 Completed Phase II Solar Urticaria (SU) Pilot Study
Condition: Solar Urticaria
Intervention: Drug: afamelanotide
19 Not yet recruiting Efficacy and Safety of Omalizumab in Patients With Severe Acute Urticaria
Condition: Urticaria
Intervention: Drug: omalizumab
20 Recruiting Cold Contact Urticaria Treatment With Rilonacept
Condition: Cold Contact Urticaria
Interventions: Drug: Rilonacept;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years